Product Images Sunitinib Malate

This is a description of a study evaluating the time to tumor progression in patients treated with Sunitinib Malate compared to a placebo. The study included a total of 207 patients in the Sunitinib Malate group and 105 patients in the placebo group. The median time to tumor progression in the Sunitinib Malate group was 27.3 weeks, while in the placebo group it was 6.4 weeks. The hazard ratio, which measures the risk of tumor progression, was 0.33, indicating a lower risk in the Sunitinib Malate group. This result is statistically significant with a p-value of less than 0.0001.*

The available text provides information about a comparison between Sunitinib Malate and IFN-a for a group of 375 individuals. The median survival time for Sunitinib Malate is 47.3 weeks, while for IFN-a it is 22.0 weeks. The hazard ratio between the two treatments is 0.42 (indicating a lower risk of progression with Sunitinib Malate), with a 95% confidence interval of 0.32 to 0.54. The progression-free survival probability is 8%. The data also includes a graph showing the number of subjects at risk over time. Unfortunately, the could not accurately read the remaining text.*

Not available.*